MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
|Videos|June 8, 2017
What Are Pleuromutilin Antibiotics and How Do They Work?
Author(s)Contagion Editorial Staff
Thomas File, MD, MSc explains what pleuromutilin antibiotics are and how they work.
Advertisement
Thomas File, MD, MSc, Chair of Infectious Disease Division, Summa Health in Akron, Ohio, explains what pleuromutilin antibiotics are and how they work.
Interview Transcript (slightly modified for readability):
“Pleuromutilins are a class of antimicrobial agents that have been recently developed for systemic administration for us to treat patients with certain infections. [They] work by inhibiting protein synthesis, but [they] have a unique mechanism of action which is different than other drugs that inhibit protein synthesis such that it is going to be effective against many pathogens that are resistant to these other drugs.”
DISCLOSURES: Dr. File is a consultant and on the Scientific Advisory Boards for Achaogen; Allergan; Bayer; Cempra; The Medicine’s Company; Merck; MotifBio; Nabriva; Paratek; Zavante.
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
4
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
5